An economic evaluation has recently been evaluated by the Centre for Reviews and Dissemination (CRD). They concluded that treatment for mild gestational diabetes is effective at improving maternal and neonatal outcomes.
In women with mild gestational diabetes, are the benefits of treatment with diet or insulin worth the cost?
The analysis was undertaken from a US societal perspective. It is not clear how “mild” gestational diabetes was defined.
The analysis modelled the treatment of mild gestational diabetes using data on:
- treatment effectivness from randomised trials
- costs from published US sources
- Quality-Adjusted Life-Years (QALYs) from published sources and from “conservative” estimates.
The analysis concludes:
The incremental cost per QALY gained with treatment over no treatment was $20,412.
Users of this research should consider:
- The robustness of the evidence for treatment effectiveness, which relied on a small number of poorly-reported studies.
- The perspective of the analysis was from a US payor and may not translate to other settings.
- Some indirect costs were not included in the model.
- The model was sensitive to treatment costs.
Read the full text of the the critical appraisal by the Centre for Reviews and Dissemination.
Ohno MS, Sparks TN, Cheng YW, Caughey AB. Treating mild gestational diabetes mellitus: a cost-effectiveness analysis. Am J Obstet Gynecol. 2011 Sep;205(3):282.e1-7.